Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8DZKI)

Drug Name

TNP-2092 Drug Info

Synonyms

UNII-W2P7EF7O6O; W2P7EF7O6O; CBR-2092; CHEMBL4594404; 3-((E)-((4-((1-((3R)-1-(3-Carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizin-8-yl)-3-pyrrolidinyl)cyclopropyl)methylamino)-1-piperidinyl)imino)methyl)rifamycin; Rifamycin, 3-((E)-((4-((1-((3R)-1-(3-carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizin-8-yl)-3-pyrrolidinyl)cyclopropyl)methylamino)-1-piperidinyl)imino)methyl)-

Indication

Disease Entry	ICD 11	Status	REF
Skin and skin-structure infection	1F28-1G0Z	Phase 2	[1]
Joint infection	FA10	Phase 1	[2]

Cross-matching ID

PubChem CID: 145722022
CAS Number: CAS 922717-97-3
TTD Drug ID: DM8DZKI

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Bacterial DNA gyrase (Bact gyrase)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Grepafloxacin	DMGLX0T	Chronic bronchitis	CA20.1	Approved	[4]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[5]
Levofloxacin	DMS60RB	Acute maxillary sinusitis		Approved	[5]
Gatifloxacin	DMSL679	Acute gonococcal cervicitis		Approved	[5]
Norfloxacin	DMIZ6W2	Acute gonococcal cervicitis		Approved	[5]
Ozenoxacin	DM6KZMG	Impetigo	1B72	Approved	[6]
Sparfloxacin	DMB4HCT	Bacterial infection	1A00-1C4Z	Approved	[5]
Gemifloxacin	DMHT34O	Bacterial infection	1A00-1C4Z	Approved	[5]
Besifloxacin	DMPHXMI	Ocular inflammation	9C61.24	Approved	[7]
Finafloxacin	DMZEONG	Urinary tract infection	GC08	Approved	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Bacterial DNA topoisomerase 4A (Bact parC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prulifloxacin	DMOK965	Urinary tract infection	GC08	Approved	[9]
Pazufloxacin	DMHXTAQ	Conjunctivitis	9A60	Phase 3	[10]
Sitafloxacin	DMTV5XC	Escherichia coli infection	1A03	Phase 2/3	[11]
VB 1953	DM0YWQ4	Acne vulgaris	ED80	Phase 2	[12]
JNJ-32729463	DMQD1GN	Community-acquired pneumonia	CA40.Z	Phase 2	[13]
A-62824	DMJ6IMZ	Discovery agent	N.A.	Investigative	[14]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial DNA gyrase (Bact gyrase)	TTN6J5F	GYRA_STAAU; GYRB_STAAU	Inhibitor	[3]
Bacterial DNA topoisomerase 4A (Bact parC)	TTFK8YB	PARC_ECOLI	Inhibitor	[3]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03964493) TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection (P2_ABSSSI). U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT04294862) Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of TenNor Therapeutics.
4	Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in tar... Antimicrob Agents Chemother. 2002 Feb;46(2):582-5.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6	In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
7	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
8	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
9	Prulifloxacin: a new antibacterial fluoroquinolone. Expert Rev Anti Infect Ther. 2006 Feb;4(1):27-41.
10	Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7.
11	Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2008 Jul;62(1):98-104.
12	Clinical pipeline report, company report or official report of Vyome Therapeutics.
13	Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother. 2011 Dec;55(12):5512-21.
14	Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent anti... Bioorg Med Chem Lett. 2006 Mar 1;16(5):1272-6.